Myriad Genetics has entered into an expanded, nonexclusive global collaboration with AstraZeneca to provide companion diagnostics for AZ’s olaparib Phase III development program. Olaparib is an investigational orally active poly-ADP ribose polymerase (PARP) inhibitor being developed for the treatment of various tumor types, including BRCA-mutated breast and ovarian cancers.   Myriad will build a new lab within its Salt Lake City facility in accordance with FDA regulations for companion diagnosti...